Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?  by Guckenberger, Matthias et al.
ORIGINAL ARTICLE
Is There a Lower Limit of Pretreatment Pulmonary Function
for Safe and Effective Stereotactic Body Radiotherapy for
Early-Stage Non-small Cell Lung Cancer?
Matthias Guckenberger, MD,* Larry L. Kestin, MD,† Andrew J. Hope, MD,‡ Jose Belderbos, MD,§
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Introduction: To evaluate the influence of pretreatment pulmonary
function (PF) on survival, early and late pulmonary toxicity after stereo-
tactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer.
Methods: Four hundred eighty-three patients with 505 tumors of
early-stage non-small cell lung cancer cT1–3 cN0 were treated with
image-guided SBRT at five international institutions (1998–2010).
Sixty-four percent of the tumors were biopsy-proven and 18F-
fluorodeoxyglucose-positron emission tomography was performed
for staging in 84%. Image-guided SBRT was performed with a
median of three fractions to a median total dose of 54 Gy. Pretreat-
ment PF was available for 423 patients, and 617 posttreatment PF
tests from 270 patients were available.
Results: A large variability of pretreatment PF was observed: the
90% range of forced expiratory volume in 1 second and diffusing
capacity for carbon monoxide was 29 to 109% and 5.5 to 19.1
ml/min/mmHg, respectively. PF was significantly correlated with
overall survival but not cause-specific survival: diffusing capacity
for carbon monoxide of 11.2 ml/min/mmHg differentiated between
3-year overall survival of 66% and 42%. Radiation-induced pneu-
monitis grade II occurred in 7% of patients and was not increased
in patients with lower PF. A significant and progressive change of
PF was observed after SBRT: PF decreased by 3.6% and 6.8% on
average within 6 and 6 to 24 months after SBRT, respectively.
Changes of PF after SBRT were significantly correlated with pre-
treatment PF: PF improved for worst pretreatment PF and the largest
loss was observed for best pretreatment PF.
Conclusions: Image-guided SBRT is safe in terms of acute and chronic
pulmonary toxicity even for patients with severe pulmonary comorbidities.
SBRT should be considered as a curative treatment option for inoperable
patients with pretreatment PF as reported in this study.
Key Words: Non-small cell lung cancer, Stereotactic body radio-
therapy, Pulmonary function.
(J Thorac Oncol. 2012;7: 542–551)
Surgical treatment with lobectomy and mediastinal lymphnode dissection is the standard of care for stage I non-
small cell lung cancer (NSCLC). However, about one-third of
the patients with early-stage NSCLC are inoperable because
of medical comorbidities. Stereotactic body radiotherapy
(SBRT) is then the treatment of choice: prospective trials
consistently report excellent local control rates in the range of
90% and higher,1–5 which is significantly better compared
with control rates after conventionally fractionated radiother-
apy.6 These high rates of local tumor control are achieved by
delivering hypofractionated, escalated irradiation doses be-
yond 100 Gy biological equivalent dose (calculated with /
of 10 Gy)7,8 to the primary tumor.
Exposure of healthy normal tissue to these high irradi-
ation doses is minimized by employment of precision tech-
niques in all steps of radiotherapy treatment: accurate staging,
target delineation with consideration of breathing motion,
conformal treatment planning, and image-guided treatment
delivery. As a consequence, reported toxicity (especially
pulmonary toxicity) grade II is usually below 10%. Never-
theless, the combination of hypofractionation up to single-
fraction radiosurgery and very high biological equivalent
radiation doses raises concerns about the safety of SBRT in
this vulnerable patient population. This is especially true
because patients with extremely poor pulmonary function
(PF) are treated with SBRT: even a small loss of PF could
have deleterious effects in such a fragile patient population.
So far, however, no lower limit of PF required for safe and
effective SBRT has been reported.
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Consequently, it was the aim of this study to analyze
the influence of pre-SBRT PF on survival and also to study
radiation induced pneumonitis and post-SBRT PF in relation
to pretreatment PF. All patients were treated at one of five
institutions internationally recognized for expertise in tech-
nologically advanced radiation therapy, particularly image
guidance, with similar philosophies with respect to target
volume definitions and four-dimensional treatment planning.
MATERIALS AND METHODS
Patient Characteristics
Between 1998 and 2010, a total of 483 patients with
505 tumors of early-stage NSCLC were treated with image-
guided SBRT at one of five international institutions partic-
ipating as members of the Elekta Lung Research Group:
William Beaumont Hospital, The Netherlands Cancer Insti-
tute-Antoni van Leeuwenhoek Hospital, Thomas Jefferson
University, Princess Margaret Hospital, and University Hos-
pital Wuerzburg. Patient and treatment characteristics are
summarized in Table 1. All patients had either biopsy-proven
NSCLC (64%) or a lung nodule which were newly developed
or steadily increasing in size on computed tomography (CT)
imaging with increased 18F-fluorodeoxyglucose (FDG) up-
take on positron emission tomography (36%). The median
maximum tumor dimension was 2.6 cm (range, 0.9–8.5 cm);
tumor maximum dimension was generally limited to 5 cm;
however, 4% of the tumors were larger than 5 cm. Clinical
stage was IA in 63%, IB in 33%, IIA in 2%, or a recurrent
tumor in 1%. Centrally located tumors 2 cm from the
proximal bronchial tree were treated in four of five institu-
tions but represented only a small proportion of the study
population. For staging, FDG-PET or FDG-PET/CT scanning
was performed in 84% of the patients; a mediastinoscopy,
bone scan, head CT, or brain MRI scan were performed in
selected patients as part of the diagnostic workup in some
institutions. Pretreatment pulmonary function tests (PFTs)
were performed in the majority of the patients: forced expi-
ratory volume in 1 second (FEV1) actual (84%) and predicted
(87%); diffusing capacity for carbon monoxide (DLCO) ac-
tual 38% and predicted 66%. Table 2 shows a 2  2 table for
availability of pretreatment PFT. These 12.8% without pre-
treatment PFTs are most likely patients with good PF, where
the clinical presentation showed no obvious respiratory con-
traindication against SBRT.
Treatment Planning and Delivery
According to the institutional protocol, patients were
positioned and immobilized in one of the following devices:
arm and knee support, Stereotactic Bodyframe (Elekta AB,
Stockholm, Sweden), alpha cradle, modified alpha cradle, or
BodyFix (Elekta AB). Breathing-induced motion of the pul-
monary target was evaluated in all patients with time-re-
solved imaging, mostly using respiration-correlated CT. The
gross target volume (GTV) was contoured using CT lung
windows, and the clinical target volume (CTV) was equiva-
lent to the GTV for three of the five centers; two of five
centers added a GTV-to-CTV margin of 4 to 7 mm for
microscopic tumor extension. Breathing motion was compen-
sated using the internal target volume concept in four of five
institutions and the mean target position concept in one
institution; no institution used margins less than 5 mm.
A large number of dose fractionation schedules were
employed dependent on institutional preference. The median
volumetric prescription dose was 54 Gy (range, 18–64 Gy)
with a median dose per fraction of 12.5 Gy (range, 4.2–26
Gy) and a median number of fractions of 3 (range, 1–15).
Treatment was delivered over a median of 8 days (range,
1–27 days). Daily pretreatment verification of the target
position using volumetric image guidance was practiced in all
patients; since the end of 2005, a cone-beam CT (Elekta XVI)
was used for image-guided radiotherapy in all institutions.
TABLE 2. 2  2 Table for Availability of Pretreatment
Pulmonary Function
FEV1 Available FEV1 Not Available
DLCO available 322 (66.4%) 0 (0%)
DLCO not available 101 (20.8%) 62 (12.8%)
FEV1, forced expiratory volume in 1 sec; DLCO, diffusing capacity for carbon
monoxide.
TABLE 1. Patient and Treatment Characteristics
Characteristic Median Range %
Age (yr) 74 42–94
ECOG performance 1 0–3
Sex
Male 52
Female 48
Biopsy-proven 64
PET-staged 84
Clinical stage
IA (T1 N0) 63
IB (T2 N0) 33
IIA (T3 N0) 2
Local recurrence 1
GTV maximum dimension (cm) 2.6 0.9–8.5
3 61.3
3 38.6
Histology
Adenocarcinoma 47
Squamous cell carcinoma 32
Large cell/NOS/mixed 22
Grade
1 12
2 48
3 40
PTV prescription dose (Gy)
Single-fraction dose 12.5 4.2–26
Total dose 54 18–64
Number of fraction 3 1–15
ECOG, Eastern Cooperative Oncology Group.
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Follow-Up
All patients underwent routine follow-up including a
CT scan of the chest every 3 to 6 months for the first 2 years.
Toxicities were scored based on National Cancer Institute
Common Terminology Criteria for Adverse Events v3.0.
Routine assessment of PF was performed in two of five
institutions; there was no routine protocol in the other three
institutions. PFTs were sometimes performed in other hospi-
tals during follow-up, and these data were retrieved best as
possible.
Statistical Analysis
Statistical analyses were performed with Statistica 9.0
(Statsoft, Tulsa OK), and all statistical tests were two-sided.
A p value 0.05 was considered statistically significant.
Estimated likelihood of events was calculated using the
Kaplan-Meier method. The log-rank test was used to compare
differences between curves. Receiver operating characteris-
tics (ROC) curves were used to test prognostic factors in
predicting outcome, with their performances measured based
on the area under the ROC curve. The Student’s unpaired t
test, Pearson 2/Fisher’s exact test, and Kruskal-Wallis anal-
ysis of variance were used to compare continuous and cate-
gorical variables between groups. The Student’s paired t test
and Wilcoxon matched pairs test were used to compare
dependent samples.
RESULTS
Descriptive Analysis of Pretreatment PF
A wide spectrum of pretreatment PF was observed,
which is illustrated in Figure 1. Median actual FEV1 was 1.4
L (range, 0.4–4.4 L), median predicted FEV1% was 63%
(range, 21–186%), median actual DLCO was 10.9 ml/min/
mmHg (range, 3.4–27.6 ml/min/mmHg), and median pre-
dicted DLCO% was 52% (range, 10–103%). The median
FIGURE 1. Histogram of pretreatment pulmonary function: FEV1 (A), FEV1% (B), DLCO (C), and DLCO% (D).
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interval between PFT and start of SBRT was 1.5 months,
ranging between 0.2 and 11.6 months; this interval was
longer than 3 months in 10.9% of the treatments. Age and
performance status (Eastern Cooperative Oncology Group) of
the patients were not significantly associated with pretreat-
ment PF.
Differences in pretreatment PFTs were highly signifi-
cant between the five institutions for FEV1 (p  0.0025),
FEV1% (p  0.0015), and DLCO% (p  0.001). Sufficient
patients with pretreatment DLCO testing were available from
two institutions (William Beaumont Hospital and Princess
Margaret Hospital) only, and DLCO was significantly differ-
ent (p  0.02). Table 3 summarizes pretreatment PFT data
separately for the five institutions.
Influence of Pretreatment PF on Pneumonitis
and Survival
Radiation-induced pneumonitis grade II (treatment
with steroids) was observed in 7% of all patients after a
median interval of 4 months (range, 0.7–12 months);
pneumonitis grade III (treatment with steroids and oxy-
gen supply requirement) was observed in 2%. There was
no significant association between any parameter of pre-
treatment PF and the risk of either grade II or III
pneumonitis.
Median follow-up was 14.5 months ranging between
0.4 months and 7.3 years. Two- and 3-year cause-specific
survival was 87% and 77%, respectively. There was no
association between any parameter of pretreatment PF and
cause-specific survival. Two- and 3-year overall survival
(OS) rates were 60% and 48%, respectively. ROC analysis
between PF and OS showed significant results for DLCO
(p  0.008) and DLCO% (p  0.03); optimal cutoff values
were 11.2 ml/min/mmHg for DLCO and 51% for DLCO%
(Table 4). The use of these cutoff values showed 3-year OS
rates of 66% and 42% (p  0.0009) for DLCO 11.2
ml/min/mmHg and 11.2 ml/min/mmHg, respectively (Fig-
ure 2). After grouping patients into quartiles according to
pretreatment DLCO, 3-year OS rates of 31%, 51%, 67%, and
62% were observed for the quartiles with lowest to highest
pretreatment PF.
TABLE 3. Pretreatment Pulmonary Function for the Total Patient Cohort and
Separately for the Five Institutions
n Median Min Max
5th
Percentile
95th
Percentile
FEV1 (L/sec)
All 425 1.4 0.4 4.4 0.7 2.7
WBH 84 1.3 0.4 3.0 0.6 2.3
NKI-AVL 163 1.5 0.4 4.4 0.8 2.7
TJU 14 1.3 0.7 1.6 0.7 1.6
PMH 116 1.4 0.5 3.8 0.6 2.6
UHW 48 1.2 0.7 2.8 0.7 2.7
FEV1% (%)
All 430 63 21 186 29 109
WBH 84 63 22 123 32 100
NKI-AVL 170 65 21 153 31 102
TJU 14 62 34 105 34 105
PMH 115 68 21 186 29 116
UHW 47 51 24 94 25 88
DLCO (ml/min/mmHg)
All 192 10.9 3.4 27.6 5.5 19.4
WBH 75 9.5 3.4 19.9 4.7 18.0
NKI-AVL 0
TJU 10 13.0 5.9 19.1 5.9 19.1
PMH 100 11.7 4.4 27.6 5.8 21.0
UHW 7 9.9 5.7 14.7 5.7 14.7
DLCO% (%)
All 332 52 10 103 25 88
WBH 75 43 17 90 19 74
NKI-AVL 137 54 10 103 29 86
TJU 9 60 27 84 27 84
PMH 102 56 18 97 30 94
UHW 9 36 20 58 20 58
FEV1, forced expiratory volume in 1 sec; DLCO, diffusing capacity for carbon monoxide; WBH, William Beaumont
Hospital; NKI-AVL, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital; TJU, Thomas Jefferson
University; PMH, Princess Margaret Hospital; UHW, University Hospital Wuerzburg.
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Posttreatment PF
A total of 617 PFTs from 270 patients were available
for analysis. Changes of PF over time are displayed in Figure
3. Short-term (6 months) and long-term (6  24
months) intrapatient changes of PF were analyzed; the num-
ber of PFT data beyond 24 months after SBRT was insuffi-
cient for reliable statistical analysis. For all four evaluated
PFT parameters, a significant and progressive decline was
observed: short-term and long-term changes of PF were
3.6% and 6.8% on average for all PF parameters. How-
ever, both large decreases and increases of PF after SBRT
were observed for individual patients. Relative differences
compared with pretreatment PF are shown in Table 5. Short-
term and long-term changes of PF were smallest for FEV1
with no significant differences between the other three exam-
ined PF parameters FEV1%, DLCO, and DLCO%.
The association of pretreatment PF with post-SBRT PF
changes was evaluated. A significant correlation between
pretreatment PF and relative changes of long-term PF was
observed for FEV1 (p  0.001), FEV1% (p  0.001), and
DLCO (p  0.02). Long-term relative change of DLCO was
4.4%  21% and 18%  14% for patients with the lowest
and highest quartile of pretreatment DLCO, respectively (p
0.03) (Figure 4). Age and ECOG performance status were not
correlated with changes of PF.
DISCUSSION
Pretreatment PF and Medical Inoperability
This retrospective analysis comprised 483 patients treated
with image-guided SBRT for early-stage NSCLC at five inter-
national institutions. The large majority of the patients have been
discussed in multidisciplinary meetings where lobectomy is
considered as the standard of care for stage I NSCLC. Pulmo-
nary comorbidity with insufficient PF has been reported as the
most frequent reason for inoperability and subsequent SBRT
treatment. In the prospective phase II trial by Ricardi et al.,4 51
patients were medically inoperable, and the contraindication for
surgery was chronic obstructive pulmonary disease (COPD) and
cardiovascular morbidity in 31 and 15 patients, respectively. In
the Swedish phase II trial by Baumann et al.,1 inoperability was
triggered by COPD and cardiovascular disease in 65% and 25%
of the patients, respectively.
In our patient cohort, a large variability of pretreatment
PF has been observed: the 90% range of FEV1 and DLCO%
was 0.7 to 2.7 L and 25 to 88%, respectively. Consequently,
FIGURE 2. Kaplan-Meier curves of overall sur-
vival for DLCO 11.2 ml/min/mmHg (n  84)
and 11.2 ml/min/mmHg (n  97).
TABLE 4. ROC Analysis of Pretreatment Pulmonary Function and Overall Survival (OS) and
Log-Rank Test Using Cutoff Values from ROC Analysis
ROC Analysis
Log-Rank Test
AUC p Cutoff
3a OS: PF
> Cutoff
3a OS: PF
< Cutoff p
FEV1 (L) 0.511 0.73 0.9 48% 38% 0.02
FEV1% (%) 0.525 0.4 57.0 52% 38% 0.03
DLCO (ml/min/mmHg) 0.621 0.008 11.2 66% 42% 0.0009
DLCO% (%) 0.576 0.03 51.0 62% 42% 0.01
FEV1, forced expiratory volume in 1 sec; DLCO, diffusing capacity for carbon monoxide.
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the spectrum of patients treated with SBRT ranged between
pulmonary severely ill and pulmonary healthy patients. Pa-
tients are considered as suitable for lobectomy with preoper-
ative FEV1 1.5 L and DLCO% 60%9,10; for patients with
lower values, predicted postoperative FEV1% and DLCO%
should be 30%. The proportion of patients with pretreat-
ment FEV1 1.5 L and DLCO% 60% was 42.2% and
34.6%, respectively. In addition, significant differences were
observed between the five institutions: the proportion of
patients with pretreatment FEV1 1.5 L or DLCO% 60%
varied between 23% at the University Hospital Wuerzburg
and 56% at The Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital. Consequently, pulmonary comor-
bidities were most likely not the reason for SBRT instead of
surgery in these patients.
Two reasons could explain these unexpected high pro-
portions of patients without pulmonary contraindication for
lobectomy in some of the institutions. (1) The ratio of
pulmonary and cardiovascular comorbidity triggering SBRT
could vary between the geographical regions and associated
institutions. However, cardiovascular comorbidity was not
recorded in our multi-institutional database. (2) The excellent
and consistent clinical results of SBRT could broaden the
indication of SBRT compared with surgery. Japanese
groups have reported SBRT in medically operable patients
refusing surgery, and OS in this favorable cohort ap-
proached surgical results.11 A trend to preference of non-
invasive SBRT instead of surgery may especially be true
for an elderly patient population: median age was 74 years
and about one-fourth of the patients were older than 80
years in our cohort.
As a result of these observations, we recently added the
parameter “medical inoperability” to our database. Results of
89% of the patients are available: 13% of these patients were
considered as operable but refused surgery. A further study
will analyze this cohort more in detail.
FIGURE 3. Changes of PF over time: FEV1 (A), FEV1% (B), DLCO (C), and DLCO% (D).
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Influence of Pretreatment PF on OS
Pretreatment PF was significantly associated with OS
and this association was strongest for DLCO. In the surgical
literature, the predictive value of pretreatment DLCO on
postoperative morbidity and mortality is well established.10
Decreased OS has been reported for patients with lower
pretreatment DLCO receiving concurrent radiochemotherapy
for locally advanced NSCLC12 and limited disease SCLC.13
Few studies have analyzed the influence of pretreatment PF
on OS after SBRT treatment. Stephans et al.14 reported
significantly longer OS for patients with FEV1% below the
median of the study population; this was explained by ac-
counting for the competing risk of death due to cardiac
morbidity in the patients with better PF. The study by Haas-
beek et al.15 limited the analysis to patients 75 years, and
pretreatment FEV1% with a cutoff of 50% was significantly
correlated with OS in the multivariate analysis.
Pretreatment DLCO of 11.2 ml/min/mmHg differenti-
ated between 3-year OS rates of 66% (n  84) and 42% (n 
97). For the good PF group, this OS is highly promising and
is better compared with all recent prospective phase II trials
on SBRT for stage I NSCLC.1–5 Furthermore, results are
approaching the Japanese data of medically operable patients
who refused surgery and actively opted for SBRT.11 OS was
significantly lower for the poor PF group. However, their
median OS of 2.5 years is still substantially longer compared
with OS of 6 to 14 months, which is reported for untreated
stage I NSCLC.16–18
Because COPD is the major cause of inoperability in
lung cancer patients and simultaneously a significant com-
peting risk factor for death, we analyzed our data with respect
to severity of COPD. Two-year OS was 66%, 55%, and 51%
for FEV1 50%, 35%  FEV1 50%, FEV1 35% in our
cohort, respectively. This is in good agreement with recent
data by Palma et al.,19 who analyzed SBRT in patients with
severe COPD: 2-year OS was approximately 61% in a patient
cohort with median FEV1  38%. Two-year OS is approx-
imately 90% and 80% for noncancer patients with COPD
stages I and II and severe COPD stage III,20–23 respectively.
This absolute difference of about 25 to 30% between non-
cancer COPD patients and our stage I NSCLC patient cohort
is not fully explained by the cancer-specific mortality of 13%
after SBRT. Potential reasons for this difference are (1)
toxicity of SBRT and (2) differences in other patient charac-
teristics influencing OS. As the most obvious, median age
was 4 years older in our patient cohort compared with the
studies about the natural course of COPD, which are cited
above. Unfortunately, other important prognostic parameters
such as Charlson comorbidity index, body mass index, dys-
pnea, smoking status, and exercise capacity are not available
for our patient cohort.
Influence of Pretreatment PF on Acute and
Late Pulmonary Toxicity
A low rate of radiation-induced pneumonitis was ob-
served, and pretreatment PF was not associated with the risk
of pneumonits grade II and grade III.
Posttreatment PF was analyzed as surrogate for chronic
pulmonary toxicity after SBRT. A significant and progressive
decrease of PF was observed within 24 months after SBRT.
However, the amount of PF loss was small: short-term and
long-term changes of PF were 3.6% and 6.8% averaged
over all patients and PF parameters. This significant decrease
of PF may well be explained by the natural history of the
underlying cardiac and pulmonary comorbidities.24 In addi-
tion, large interpatient variability of post-SBRT PF changes
was observed. Age of the patients, ECOG performance status,
and pneumonitis after image-guided SBRT were not corre-
lated with PF changes.
This finding of minimal influence of SBRT on PF is
supported by data in the literature. An overview is given in
Table 6. Three studies reported no significant PFT changes
after SBRT,14,25,26 and small changes of 3% are described
by Bral et al.3 One study observed a significant improvement
of DLCO with no changes of FEV1.27 Discordant results
between DLCO and FEV1 are reported by three studies,
TABLE 5. Relative Difference between Pre- and Posttreatment Pulmonary Function (PF) within
6 mo after Treatment (Short Term) and 6–24 mo after Treatment (Long Term)
n
Relative Difference between Pre- and Posttreatment PF (%)
Median Min Max 5th Percentile 95th Percentile p
FEV1
Short term 194 1.8 55.3 157.9 28.2 27.3 0.005
Long term 98 4.7 42.9 165.8 29.9 27.0 0.02
FEV1%
Short term 193 1.7 61.5 178.8 34.1 53.4 0.03
Long term 100 6.7 51.2 260.0 39.5 51.2 0.001
DLCO
Short term 112 6.9 78.2 99.1 33.3 33.3 0.007
Long term 38 9.7 42.6 43.9 34.6 35.0 0.0006
DLCO%
Short term 151 4.0 84.4 105.6 41.9 35.4 0.01
Long term 75 6.1 44.2 116.7 42.1 44.4 0.04
FEV1, forced expiratory volume in 1 sec; DLCO, diffusing capacity for carbon monoxide.
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where two reported a decrease of DLCO and no changes of
FEV128,29 and one vice versa.30 In addition, Stephans et al.14
reported no correlation between pretreatment PF and post-
SBRT changes of PF.
How does this minimal change of PF after SBRT
compare with surgical treatment of stage I NSCLC? Similar
to SBRT, wedge resection seems to have limited influence on
posttreatment PF31; however, oncological outcome after
wedge resection is suboptimal and seems to be inferior to
SBRT.32 Anatomical segmentectomy is most likely the sur-
gical technique most comparable to SBRT, and a decrease of
PF (most frequently FEV1%) by 10 to 15% is consistently
reported in the literature.33–37 Image-guided SBRT compares
at least favorably to these results.
Pretreatment PF was significantly associated with post-
SBRT PF changes: an increase of PF was observed for the
patient quartile with the worst pretreatment PF (12% aver-
aged over the four evaluated PFTs) and the largest loss of PF
was seen in the quartile with the best pretreatment PF
(14%). If SBRT would negatively affect PF, one would
expect the opposite with largest PF loss in patients with worst
pretreatment PF.
We consequently interpret these findings that SBRT
has only very limited acute and late pulmonary toxicity
even in patients with poor PF. This could be explained by
advanced planning methods and precise delivery of the
planned irradiation doses using volumetric image guid-
ance, which all resulted in minimal lung damage. We did
not find a minimum PF which is required for safe practice
of SBRT. The lower 10th percentile of FEV1% and DLCO
was 33% and 6.4 ml/min/mmHg in our large cohort of 483
patients: these values are considered as preliminary and
conservative recommendations for safe practice of SBRT
because 10% of our patients were treated with SBRT
FIGURE 4. Relative changes of PF 6–24 months after SBRT in relationship to pretreatment PF (patients grouped into quar-
tiles): FEV1 (A), FEV1% (B), DLCO (C), and DLCO% (D). Shown are mean values and 1 SD.
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despite lower PF. However, prospective evaluation of this
important question is required.
Limitations
Some limitations of our study need to be discussed.
There was no common protocol for pre- and posttreatment
analysis of PF. Although post-SBRT PF was assessed at each
follow-up visit in two institutions, this was done in irregular
intervals at the other three institutions. PF testing could have
been triggered by worsening of the patients’ performance and
clinical status, which could introduce a bias into the analysis.
In addition, stable PF after SBRT does not ultimately prove
the absence of pulmonary toxicity: it has been clearly shown
that a multidimensional scale of PF test, body mass index,
dyspnea, and exercise capacity is a better prognostic param-
eter compared with only PF tests.20 However, these parame-
ters were not available in our multi-institutional database.
CONCLUSIONS
OS after SBRT for stage I NSCLC is significantly
influenced by pretreatment PF, which needs to be considered
when comparing results after SBRT with other treatment
options like surgery or best supportive care. Safety in terms
of acute and late pulmonary toxicity was observed irrespec-
tive of pretreatment PF. All patients with pulmonary comor-
bidities and PF in the reported range should therefore be
discussed in a multidisciplinary setting and should be in-
formed about SBRT as safe and curative treatment option.
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